ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Genomics and Proteomics"

  • Abstract Number: 1741 • ACR Convergence 2025

    Chronic JDM Plasma Proteomic Signature Reflects Inflammation from Immune and Tissue-resident Muscle and Skin

    Marianne Kerski1, Celine Berthier1, Benjamin Klein1, Li Chen2, Christine Goudsmit2, Sophia Matossian1, Qinmengge Li3, Chioma Madubata4, Jessica Neely5, J. Michelle Kahlenberg1 and Jessica Turnier6, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, 3University of Michigan, Ypsilanti, MI, 4UCSF, SF, CA, 5UCSF, San Francisco, CA, 6University of Michigan, Saline, MI

    Background/Purpose: Juvenile dermatomyositis (JDM) and childhood-onset SLE (cSLE) are systemic autoimmune diseases characterized by overlapping yet distinct clinical manifestations and treatment responses. In this study,…
  • Abstract Number: 1702 • ACR Convergence 2025

    Powerful and Accurate Case-Control Analysis of Spatially Resolved Molecular Data in Autoimmune Disease

    Yakir Reshef1, Lakshay Sood1, Michelle Curtis1, Laurie Rumker2, DANIEL STEIN3, Mukta Palshikar1, Saba Nayar4, Andrew Filer5, Anna Helena Jonsson6, ilya Korsunsky7 and Soumya Raychaudhuri7, 1Brigham and Women's Hospital, Boston, 2Broad Institute, Boston, 3Harvard University, Boston, 4University of Birmingham, Birmingham, United Kingdom, 5The University of Birmingham, Birmingham, United Kingdom, 6University of Colorado School of Medicine, Aurora, CO, 7Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Autoimmune diseases such as rheumatoid arthritis (RA) involve complex spatial organization of immune and stromal cells within inflamed tissues. As spatial molecular profiling methods…
  • Abstract Number: 1181 • ACR Convergence 2025

    Clinical Relevance of Tumor Necrosis Factor Superfamily Cytokines

    Robert Corty1, Gul Karakoc1, Ahmad Jawdat2, Hui Yu3, Jonathan Mosley4, Michael Stein1 and Vivian Kawai5, 1Vanderbilt University Medical Center, Nashville, TN, 2University of Alabama at Birmingham, Birmingham, 3University of Miami, Miami, 4UT Southwestern Medical Center, Dallas, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The tumor necrosis factor superfamily (TNFSF) includes 48 proteins involved in immune activation, inflammation, and cell death and represent an area of intense focus…
  • Abstract Number: 1000 • ACR Convergence 2025

    A Deep-Learning Based Approach Uncovers Novel Mediators of Micro-RNA Restraint of Type-2 Immunity

    Shaan Sekhon1, Robin Kageyama2, Neil Sprenkle3, Hannah Happ2, Eric Wigton2, Heather Pua3 and Mark Ansel2, 1University of California, San Francisco, Berkeley, 2University of California, San Francisco, San Francisco, 3Vanderbilt University, Nashville

    Background/Purpose: MicroRNAs, such as miR-24 and miR-27, co-expressed within the Mirc11 and Mirc22 clusters, orchestrate a regulatory network critical to Th2 cell differentiation and cytokine…
  • Abstract Number: 0889 • ACR Convergence 2025

    Potentially pathogenic memory CD4 T cells with a B cell helper phenotype expand in ACPA+ individuals during progression to rheumatoid arthritis

    Ziyuan He1, Marla Glass1, Pravina Venkatesan2, Alexandra Ferrannini3, Marie Feser4, Christy Bennett1, David Boyle5, Kristen Demoruelle6, Kristine Kuhn7, Fan Zhang8, Thomas Bumol9, Ananda Goldrath3, Peter Skene3, V. Michael Holers10, Xiaojun Li1, Adam Savage1, Gary Firestein11, Kevin Deane12, Troy Torgerson13 and Mark Gillespie1, 1Allen Institute for Immunology, Seattle, WA, 2Allen Insitute, Seattle, WA, 3Allen Institute for Immunology, Seattle, 4University of Colorado Anschutz Medical Campus, Aurora, CO, 5UCSD, La Jolla, CA, 6University of Colorado Anschutz Medical Campus, Golden, CO, 72022 - 2023 / Adult/ University of Colorado, Aurora, CO, 8The University of Colorado, Aurora, CO, 9Allen Institute for Immunology, San Diego, CA, 10University of Colorado, Denver, CO, 11University of California, San Diego, San Diego, CA, 12University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 13Allen Institute for Immunology, Enumclaw, WA

    Background/Purpose: Prior to the onset of clinically apparent inflammatory arthritis (IA)/synovitis (clinical RA), ACPA+ ‘at-risk’ individuals (ARI) show alterations in the abundance of effector T…
  • Abstract Number: 0795 • ACR Convergence 2025

    Molecular Stratification of Rheumatoid Arthritis Patients by Multi-Omics Integration Reveals Disease Status and Predictors of Therapeutic Response

    Ismael Sanchez-Pareja1, Daniel Toro2, Carlos Pérez Sánchez3, Laura muñoz-Barrera1, Tomás Cerdó1, Elena Moreno-Caño4, Sagrario Corrales1, Lydia Formanti Alonso5, Rafaela Ortega-Castro6, Jerusalén Calvo5, Lourdes Ladehesa7, Concepción Aranda-Valera5, M Carmen Abalos-Aguilera8, Christian Merlo-Ruiz8, MARIA ANGELES AGUIRRE ZAMORANO1, Marta Alarcon-Riquelme9, Alejandro Escudero Contreras5 and Chary López pedrera10, 1Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 2GENYO / Karolinska Institutet, Granada / Stockholm, Spain, 3Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 4IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, 5IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 6Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 7IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, 8Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 9Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 10Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain

    Background/Purpose: To characterize molecular profiles of RA patients through multi-omics integration and evaluate their associations with disease status and therapeutic response to csDMARDs, TNF inhibitors…
  • Abstract Number: 0329 • ACR Convergence 2025

    Machine Learning-Based Model to Predict Rapid Structural Progression in Knee Osteoarthritis

    Maria Fernanda Gonzalez Hernandez1, Ignacio rego Pérez2, Isabel Rodríguez Valle3, Jorge Vázquez García4, Vanesa Balboa5, Sara Relaño Fernández4, María C. de Andrés6, Lucía Lourido7, Valentina Calamia7, Rocio Paz González4, Patricia Quaranta7, Patricia Fernández-Puente4, Nicola Veronese8, Cristina Ruiz-Romero9, Natividad Oreiro10 and francisco J Blanco11, 1Instituto de Investigacion Biomedica de A Coruna (INIBIC), A coruña, Galicia, Spain, 2Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC), A Coruña, Spain, 3Instituto de Investigacion Biomedica de A Coruna (INIBIC), Coruña, Galicia, Spain, 4Instituto de Investigacion Biomedica de A Coruna (INIBIC), coruña, Spain, 5Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, coruña, Spain, 6Instituto de Investigación Biomédica de A Coruña (INIBIC), Grupo de Investigación de Reumatología (GIR), A Coruña, Spain, 7Instituto de Investigacion Biomedica de A Coruna (INIBIC), coruna, Spain, 8Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, palermo, Italy, 9Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC),, A Coruña, Spain, 10CHUAC, La Coruna, Spain, 11INIBIC-University of A Coruña, A Coruña, Galicia, Spain

    Background/Purpose: Osteoarthritis (OA) is the most common chronic joint disorder, characterized by structural cartilage and bone damage that often causes pain and disability. However, the…
  • Abstract Number: 0100 • ACR Convergence 2025

    Therapeutic Modulation of NAD+ Metabolism in Inflammatory Rheumatic Disorders by TNFi and NAD+ Precursors

    Beatriz Vellón-García1, Gema Dolores García-Delgado2, Adrián Llamas Urbano3, Yas Hanaee3, Pedro Ortiz Buitrago4, Christian Merlo5, Maria del carmen abalos-aguilera5, julio Manuel Martinez Moreno6, Iván Arias de la Rosa7, María Dolores López-Montilla8, Rafaela Ortega-Castro9, Jerusalén Calvo10, Lourdes Ladehesa11, Clementina López Medina12, María Ángeles Puche-Larrubia13, Nuria Barbarroja14, Eduardo Collantes estévez15, Alejandro Escudero-contreras5, Chary López pedrera16, Jose manuel Villalba17 and Carlos Pérez Sánchez18, 1Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, 2Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain., Cordoba, Spain, 3Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain., Cordoba, Spain, 4Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, 5Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, 6Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain, Cordoba, Spain, 7IMIBIC/FIBICO/Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso; Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Toledo, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Toledo, Spain., Córdoba, Spain, 8Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, 9Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 10IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 11IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, 12Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, 13Reina Sofia University Hospital, Granada, Spain, 14Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 15Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, 16Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 17Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, Cordoba, Spain, 18Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain

    Background/Purpose: This study aims to:Characterize the NAD+ metabolome in CIRDs and their association with clinical traits.Evaluate the impact of TNFi therapy on NAD+ metabolome alterations.Test…
  • Abstract Number: 2599 • ACR Convergence 2025

    Identification of a New Pathogenic Axis in Antiphospholipid Syndrome Linking Antiphospholipid Antibodies, Liver Function, and Circulating Proatherogenic Metabolites

    Beatriz Vellón-García1, Sagrario Corrales-Díaz-Flores2, MARIA ANGELES AGUIRRE ZAMORANO3, Ismael Sanchez-Pareja3, Laura muñoz-Barrera3, Tomás Cerdó3, Pedro Seguí-Azpilcueta4, Christian Merlo2, Maria del carmen abalos-aguilera2, Nuria Barbarroja5, Rafaela Ortega-Castro6, José-Antonio Gonzalez-Reyes7, Alejandro Escudero-contreras2, Chary López pedrera8, Jose manuel Villalba9 and Carlos Pérez Sánchez10, 1Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, 2Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, 3Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 4Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, 5Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 6Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 7Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA3)., Cordoba, Spain, 8Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 9Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, Cordoba, Spain, 10Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain

    Background/Purpose: This study aims to:1- Characterize the circulating metabolomic signature in APS patients; 2- Investigate the role of hepatic involvement in the pathophysiology of APS;…
  • Abstract Number: 0778 • ACR Convergence 2024

    Comprehensive Immune Profiling of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Patients with Autoimmune Disease

    Justin Chou1, Ricardo Grieshaber-Bouyer2, Michelle J Wu3, Christina Bergmann2, Jule Taubmann4, Fabian Müller5, Aline Bozec4, Tobias Rothe2, Andreas MAckensen6, Amber Podoll7, Jonathan Gutman7, Aiden Haghikia8, Dimitrios Mougiakakos9, Gary Tong3, Pouya Kheradpour3, Francis Kim10, Prameela Ramesan10, Brandon Kwong10, Kunbin Qu10, Bishwa Ganguly10, Dominic Borie10, James Chung10 and Georg Schett11, 1Kyverna Therapeutics, Emeryville, CA, 2Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 3Verily Life Sciences, South San Francisco, CA, 4Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 5Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, 6Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 7University of Colorado Anschutz Medical Campus, Aurora, CO, 8Otto-von-Guericke University, Magdeburg, Germany, 9Otto-von-Guericke University, Magdeburg, Germany, Magdeburg, Germany, 10Kyverna Therapeutics, Inc., Emeryville, CA, 11Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy represents a promising advancement in the treatment of autoimmune diseases, including systemic sclerosis (SSc), idiopathic inflammatory myopathy…
  • Abstract Number: 0892 • ACR Convergence 2024

    Peptides from Candidate Sjögren’s Disease Autoantigens and Salivary Gland Tissue-Enriched Proteins Eluted from Human Salivary Gland HLA-DR

    Tommi C. Taylor1, Sri Ramarathinam2, Shan Zou Chung2, Kirti Pandey2, Ananth Aditya Jupudi1, Bhuwan Khatri3, Sherri Longobardi3, Charmaine Lopez-Davis3, Astrid Rasmussen3, Kiely Grundahl3, Robert Hal Scofield3, Christopher Lessard3, Linda F. Thompson3, Anthony W. Purcell2 and A. Darise Farris3, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Monash University, Clayton, Victoria, Australia, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Sjögren’s Disease (SjD) is characterized by aberrant autoimmune reactions in lacrimal and salivary glands (SG) leading to severe dryness. Evidence for B cell help…
  • Abstract Number: 0893 • ACR Convergence 2024

    Uncovering Common and Distinctive Molecular Profiles Between Early and Stablished Rheumatoid Arthritis Through Integrative Multi-omics Analysis and Its Association with Disease Status and Clinical Response

    Ismael Sánchez Pareja1, Carlos Perez-Sanchez1, Dani Toro-Domínguez2, Laura Muñoz-Barrera1, Tomás Cerdó1, Elena Moreno-Caño3, Rafaela Ortega-Castro4, Jerusalem Calvo Gutierrez5, María Lourdes Ladehesa-Pineda6, Concepción Aranda-Valera3, María Carmen Ábalos-Aguilera7, Christian Merlo-Ruiz7, Mª Angeles Aguirre-Zamorano8, Nuria Barbarroja1, Marta Alarcon-Riquelme9, Alejandro Escudero-Contreras1 and Chary Lopez-Pedrera6, 1IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 2Fundación Progreso y Salud, Andalusian Government, Granada, 3IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, 4Hospital Reina Sofía, Cordoba, Andalucia, Spain, 5HU Reina Sofia, Cordoba, Spain, 6IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 7IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Spain, 8IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, 9Fundación Progreso y Salud, Andalusian Government, Granada, Spain

    Background/Purpose: Characterize the molecular landscape of RA patients using a multi-omic approach encompassing transcriptomics and proteomics and assess its association with disease stage and therapeutic…
  • Abstract Number: 0946 • ACR Convergence 2024

    Tissue Resident Monocyte-lineage Cells (TR-MC) Exist as Two Different Subpopulations

    Yidan Wang1, Jessica Maciuch2, Tyler Therron3, Carla Cuda2, Deborah Winter4 and Harris Perlman2, 1Northwestern University, Hanover Park, IL, 2Northwestern University, Chicago, IL, 3Northwestern University, Chicago, 4Northwestern University, Skokie, IL

    Background/Purpose: Monocytes are critical for the pathogenesis of rheumatoid arthritis (RA). However, depletion of peripheral monocytes (PM) is not sufficient to rescue disease in RA…
  • Abstract Number: 1589 • ACR Convergence 2024

    Whole Skin Gene Expression Analysis Identifies Discrete Modules That Differentiate Antinuclear Antibody Subsets in Systemic Sclerosis

    Kristina Clark1, Corrado Campochiaro2, Philip Yee3, Emma Derrett-Smith4, Voon Ong5 and Christopher Denton6, 1University of Oxford, Oxford, United Kingdom, 2IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, 3UCL, London, United Kingdom, 4University College London Division of Medicine, Birmingham, United Kingdom, 5University College London, London, England, United Kingdom, 6University College London, Northwood, United Kingdom

    Background/Purpose: Hallmark autoantibody reactivities predict different patterns of skin involvement and risk of internal organ involvement.  We have asked whether whole skin gene expression may…
  • Abstract Number: 1660 • ACR Convergence 2024

    Systemic Inflammation and Transcriptional Reprogramming Contribute to Progression to Active Rheumatoid Arthritis in ACPA+ Individuals

    Mark Gillespie1, Ziyuan He1, Adam Savage1, Pravina Venkatesan1, Marla Glass1, Lauren Okada2, Nhung Tran2, Yudong He2, Samir Rachid Zaim1, Padmapriyadarshini Ravisankar2, Christy Bennett1, Julian Reading2, Jessica Garber2, Palak Genge2, Veronica Hernandez2, Alexander Heubeck2, Erin Kawelo2, Upaasana Krishnan2, Kevin Lee2, Regina Mettey2, Blessing Musgrove2, Vaishnavi Parthasarathy2, Cole Phalen2, Charles Roll2, Tyanna Stuckey2, Morgan Weiss1, Claire Gustafson2, Qiuyu Gong2, Emma Kuan2, Tao Peng2, Lucas Graybuck2, Kristen Demoruelle3, Kristine Kuhn4, David Boyle5, Fan Zhang4, Thomas Bumol6, Ananda Goldrath2, Xiaojun Li1, V. Michael Holers7, Peter Skene1, Gary Firestein8, Kevin Deane9 and Troy Torgerson10, 1Allen Institute for Immunology, Seattle, WA, 2Allen Institute for Immunology, Seattle, 3University of Colorado Anschutz Medical Campus, Golden, CO, 4University of Colorado, Aurora, CO, 5UCSD, La Jolla, CA, 6Allen Institute for Immunology, San Diego, CA, 7University of Colorado, Denver, CO, 8University of California, San Diego, San Diego, CA, 9University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 10Allen Institute for Immunology, Enumclaw, WA

    Background/Purpose: Elevated levels of RA-associated autoantibodies (ACPA, RF) prior to the clinical onset of inflammatory arthritis (IA) define a state of risk for future development…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology